Does n-butylscopolammonium bromide cause fewer side effects than atropine when assessing bronchoconstriction reversibility in horses with heaves?
The study indicated that the bronchodilatory properties of NBB were not statistically different from those of atropine, but were of shorter duration. N-butylscopolammonium bromide was associated with fewer systemic side effects, and therefore NBB should be preferred over atropine when assessing the reversibility of airway obstruction in horses.
A very large proportion of parents of young children have concerns regarding their child, but agreement on these concerns with child health professionals is relatively low.